172 related articles for article (PubMed ID: 2908604)
41. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
Chime-Udeh E
Conn Med; 1991 Sep; 55(9):526-8. PubMed ID: 1748007
[No Abstract] [Full Text] [Related]
42. Bicalutamide versus flutamide in combination therapy.
Labrie F; Candas B
Urology; 1999 Mar; 53(3):662-3. PubMed ID: 10096411
[No Abstract] [Full Text] [Related]
43. Sex-specific action of antiandrogens on androgen induced changes in hepatic microsomal 3 beta-hydroxysteroid dehydrogenase and 5 alpha-reductase activity in the rat.
Lax ER; Schriefers H
Acta Endocrinol (Copenh); 1981 Oct; 98(2):261-6. PubMed ID: 6457494
[TBL] [Abstract][Full Text] [Related]
44. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
[TBL] [Abstract][Full Text] [Related]
45. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.
Iversen P; Melezinek I; Schmidt A
BJU Int; 2001 Jan; 87(1):47-56. PubMed ID: 11121992
[No Abstract] [Full Text] [Related]
46. 'Casodex': defining the role of antiandrogens.
McCaffrey JA; Scher HI
Cancer J Sci Am; 1997; 3(4):204-8. PubMed ID: 9263624
[No Abstract] [Full Text] [Related]
47. [Drug treatment of prostatic carcinoma].
Kool JC
Ned Tijdschr Geneeskd; 1997 Nov; 141(45):2202-3. PubMed ID: 9550808
[No Abstract] [Full Text] [Related]
48. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
[TBL] [Abstract][Full Text] [Related]
49. The influence of pharmaceutical compounds on male fertility.
Neumann F; Diallo FA; Hasan SH; Schenck B; Traore I
Andrologia; 1976; 8(3):203-35. PubMed ID: 793446
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate.
Poyet P; Labrie F
Mol Cell Endocrinol; 1985 Oct; 42(3):283-8. PubMed ID: 3930312
[TBL] [Abstract][Full Text] [Related]
51. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
52. Adrenal androgen blockade in relapsed prostate cancer.
Geller J; Albert JD
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1127-31. PubMed ID: 2934257
[TBL] [Abstract][Full Text] [Related]
53. [The pharmacologic profile of flutamide].
Racca S; Di Carlo F
G Ital Chemioter; 1985; 32(1):7-11. PubMed ID: 2937678
[No Abstract] [Full Text] [Related]
54. Experience with flutamide in previously untreated patients with advanced prostatic cancer.
Sogani PC; Whitmore WF
J Urol; 1979 Nov; 122(5):640-3. PubMed ID: 501817
[TBL] [Abstract][Full Text] [Related]
55. Antiandrogen monotherapy in the management of advanced prostate cancer.
Kaisary AV
Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906
[TBL] [Abstract][Full Text] [Related]
56. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion.
Schuurmans AL; Bolt J; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):849-53. PubMed ID: 2149505
[TBL] [Abstract][Full Text] [Related]
57. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
58. Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma.
Geller J
Urol Clin North Am; 1991 Feb; 18(1):83-91. PubMed ID: 1825145
[TBL] [Abstract][Full Text] [Related]
59. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
Waxman J
Prog Clin Biol Res; 1989; 303():61-8. PubMed ID: 2528741
[No Abstract] [Full Text] [Related]
60. Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.
Pavone-Macaluso M; Cacciatore M; Daricello G; Pavone C; Serretta V
Ann N Y Acad Sci; 1990; 595():328-33. PubMed ID: 2375611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
